1. MASH: Metabolic Dysfunction-associated Steatohepatitis; HAE: Hereditary Angioedema; NAION: Non- Arteritic Anterior Ischemic Optic Neuropathy.

2. In December 2023, we granted Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) exclusive rights to develop, manufacture, and commercialize RBD7022 in mainland China, Hong Kong, and Macau.

3. RBD7007 and RBD2080 are also under investigation as a potential treatment for autoimmune diseases.

4. Patient enrollment for RBD4059’s phase 2a trial for coronary artery disease in Sweden was completed in February 2025. This phase 2a trial is expected to be completed by the end of 2025.

5. RBD5044’s CTA to the EMA for phase 2 trial was approved in October 2024. This phase 2 trial was initiated in Sweden in January 2025 in patients with mixed dyslipidemia.

6. Patient enrollment for RBD1016’s phase 2 global MRCT for treating CHB was completed in November 2024. This phase 2 global MRCT is expected to be completed by the end of 2025.

7. RBD1016’s phase 2a trial for treating CHD was commenced in Sweden in August 2024 and is expected to be completed by the end of 2026.